CLOs on the Move


 
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.keryx.com
  • One Marina Park Drive Twelfth Floor
    Boston, MA USA 02210
  • Phone: 212.531.5965

Executives

Name Title Contact Details

Similar Companies

DSM PTG

DSM PTG, Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioReliance Corporation

BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and

Atossa Genetics

Atossa Genetics is a healthcare company offering proprietary medical devices and laboratory services in women`s health. Our laboratory services are offered through our wholly owned subsidiary, the National Reference Laboratory for Breast Health (NRLBH)

Scientia Advisors

Scientia Advisors is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Biosciences

Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes. The company`s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential. In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua`s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents. Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua`s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.